ORAI1 and pulmonary arterial hypertension: We also found that the inhibition of activin receptor II B with bimagrumab has no consequence on Orai1 overexpression in PAH-hPASMCs, suggesting that CM5480 monotherapy could be complementary to sotatercept treatment.